|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2100052294 |
|
最近更新日期: Date of Last Refreshed on: |
2022-04-26 18:04:12 |
|
注册时间: Date of Registration: |
2021-10-24 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
低阿片多模式镇痛方案对老年患者术后恢复质量的影响:一项单中心、前瞻、随机、对照研究 |
|
Public title: |
Effect of low opioid multimodal analgesia on postoperative recovery quality in elderly patients: a single center, prospective, randomized, controlled study |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
低阿片多模式镇痛方案对老年患者术后恢复质量的影响:一项单中心、前瞻、随机、对照研究 |
|
Scientific title: |
Effect of low opioid multimodal analgesia on postoperative recovery quality in elderly patients: a single center, prospective, randomized, controlled study |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
杜娟 |
研究负责人: |
杜娟 |
|
Applicant: |
Du Juan |
Study leader: |
Du Juan |
|
申请注册联系人电话: Applicant telephone: |
+86 13583522560 |
研究负责人电话: Study leader's telephone: |
+86 13583522560 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
641181767@qq.com |
研究负责人电子邮件: Study leader's E-mail: |
641181767@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山东省烟台市芝罘区毓璜顶东路20号 |
研究负责人通讯地址: |
山东省烟台市芝罘区毓璜顶东路20号 |
|
Applicant address: |
20 Yuhuangding Road East, Zhifu District, Yantai, Shandong |
Study leader's address: |
20 Yuhuangding Road East, Zhifu District, Yantai, Shandong |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
烟台毓璜顶医院 |
||
|
Applicant's institution: |
Yantai Yuhuangding Hospital |
||
|
研究负责人所在单位: |
烟台毓璜顶医院 |
||
|
Affiliation of the Leader: |
Yantai Yuhuangding Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
烟毓医伦理审(2021-321)号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
烟台毓璜顶医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Yantai Yuhuangding Hospital Ethics Committee |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-09-15 00:00:00 |
||
|
伦理委员会联系人: |
高振利 |
||
|
Contact Name of the ethic committee: |
Gao Zhenli |
||
|
伦理委员会联系地址: |
山东省烟台市芝罘区毓璜顶东路20号 |
||
|
Contact Address of the ethic committee: |
20 Yuhuangding Road East, Zhifu District, Yantai, Shandong |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
烟台毓璜顶医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Yantai Yuhuangding Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山东省烟台市芝罘区毓璜顶东路20号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
20 Yuhuangding Road East, Zhifu District, Yantai, Shandong |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
山东省医学会临床科研专项资金 |
||||||||||||||||||||||
|
Source(s) of funding: |
Special fund for clinical scientific research of Shandong Medical Association |
||||||||||||||||||||||
|
Target disease: |
N/A |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
I期临床试验 | ||||||||||||||||||||||
|
Study phase: |
1 |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
本课题拟探索针对老年患者的低阿片围术期多模式镇痛方案,促进术后康复。 |
||||||||||||||||||||||
|
Objectives of Study: |
This topic intends to explore a low-opioid perioperative multimodal analgesia program for elderly patients to promote postoperative recovery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
研究组患者入室后静脉注射帕瑞昔布钠40mg。全麻诱导前静脉泵注负荷剂量右美托咪定0.7μg/kg(持续泵注约10min),并恒速静脉输注右美托咪定0.5μg/kg/h至术毕前30min,对照组泵注等量生理盐水。研究组中腹腔镜手术切皮前以0.5%罗哌卡因行切口局部浸润麻醉,开腹手术在B超引导下行双侧腹横肌平面神经阻滞(每侧0.375%罗哌卡因20ml),对照组不实施此操作。术中镇痛以输注瑞芬太尼维持。两组术后镇痛均采用负荷剂量+患者自控静脉(PCIA),手术结束前15 min对照组和研究组分别给予舒芬太尼5μg或布托啡诺0.5mg和帕洛诺司琼0.25 mg,患者自控镇痛泵药物配制:研究组右美托咪定0.1μg/kg/h(最大剂量300μg)+布托啡诺0.125 mg/kg(最大剂量10mg);对照组舒芬太尼1.25μg/kg(最大剂量100μg)。持续+注药设定总量100 ml,速率为2 ml/h,自控镇痛量为0.5ml,锁定时间为15 min。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
Patients in the study group were injected with parecoxib sodium 40 mg intravenously after entering the room. The loading dose of dexmedetomidine was 0.7μg/ kg before induction of general anesthesia (continuous pumping for about 10min), and dexmedetomidine 0.5 μg/kg/h was injected intravenously at a constant rateto 30min before the operation, the control group was pumped with the same amount of normal saline. In the study group, 0.5% ropivacaine was used for incision local infiltration anesthesia before laparoscopic skin incision, and bilateral transverse abdominal muscle plane nerve block under the guidance of B-ultrasound during laparotomy (20ml of 0.375% ropivacaine on each side) , the control group did not perform this operation. The intraoperative analgesia was maintained by infusion of remifentanil. The postoperative analgesia of the two groups was load dose + patient-controlled intravenous (PCIA). 15 minutes before the end of the operation, the control group and the study group were given sufentanil 5 minutes respectively μ G or butorphanol 0.5mg and palonosetron 0.25mg, patient-controlled analgesia pump drug preparation: Dexmedetomidine 0.1μg/kg/h in the study group (maximum dose 300μg) + butorphanol 0.125 mg /kg (maximum dose 10 mg); sufentanil 1.25μg/kg in the control group (maximum dose 100μg) The total amount of continuous + injection was 100 ml, the rate was 2 ml/h, the patient-controlled analgesia was 0.5 ml, and the locking time was 15 min. |
||||||||||||||||||||||
|
纳入标准: |
1. ASA Ⅱ或III级; |
||||||||||||||||||||||
|
Inclusion criteria |
1. ASA II or III; |
||||||||||||||||||||||
|
排除标准: |
1.心功能严重异常; |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Severely abnormal cardiac function; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2021-11-01 00:00:00至 To 2023-09-30 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2021-11-01 00:00:00 至 To 2023-09-30 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
随机数字表由统计人员提供,利用SAS软件按B1、B2组1:1的比例随机化方法产生随机编码,借助统计软件SAS过程语句,给定种子数,产生受试者所接受处理的随机编码表。筛选合适的患者,按就诊先后顺序依次分入随机编码对应的处理组别。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
The random number table is provided by the statistician. The random code is generated by using SAS software according to the 1:1 ratio of B1 and B2 groups. With the help of SAS process statement of statistical software and given the number of seeds, the random code table processed by the subject |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
实验结束后6个月共享数据,共享方式为resman数据库 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
Six months after the experiment, the data was shared in resman database |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
CRF和EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
CRF and EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |